"Mind in Motion": Multimodal Imaging of Brain Activity to Investigate Walking and Mobility Decline in Older Adults
NCT ID: NCT03737760
Last Updated: 2025-07-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
279 participants
OBSERVATIONAL
2019-04-19
2025-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Brain Connectivity Between Visual Input and Movement
NCT00376545
Brain Activity in Visual-Motor Behavior
NCT00077038
Brain Activity During Production of Movement
NCT00029939
fMRI Connectivity in Fracture Hip Patients
NCT02997930
Neural Representations of Memory Transformation (MEM_TRANS)
NCT06862622
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The investigators plan to enroll 200 community-dwelling men and women age 70+ years.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Older Adults
Community-dwelling men and women age 70+ years
No interventions assigned to this group
Younger Adults
Healthy young adults, age 20-40 years for baseline assessments only
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Short Physical Performance Battery (SPPB) \<10 (45% of the sample will have an SPPB \< 8) for moderate to low functioning older adults; SPPB\>=10 for high functioning older adults
* Able to complete the 400 m walk test within 15 minutes without sitting or the help of another person and without a walker, a cane is allowed
* Willingness to undergo all testing procedures
* English speaking
* Willingness to be enrolled for 1.25 to 3.5 years, depending on enrollment date.
* Healthy men and women aged 20-40 years old
* Willingness to undergo all testing procedures
* English speaking
Exclusion Criteria
* Severe visual impairment or corrected visual acuity less than 20/40, which would preclude completion of the assessments;
* Not meeting MRI eligibility (e.g. metal implants, pacemaker, etc.)
* Clinically diagnosed vestibular dysfunction;
* Unwilling or unable to do an over-ground version of the uneven terrain task without assistive device;
* Develops chest pain or severe shortness of breath during physical stress;
* Stroke or other brain injury within the past three years;
* Current presence of motor deficits caused by a stroke or other brain injury;
* Diagnosis of dementia or taking cholinesterase inhibitors (Aricept, Exelon, Razadyne, Namenda, or Namzaric);
* Any major ADL disability (unable to feed, dress, bath, use the toilet, or transfer);
* Report of severe lower extremity pain that significantly limits mobility;
* Diagnosis or treatment for rheumatoid arthritis;
* Lives in a nursing home; persons living in assisted or independent housing will not be excluded;
* Receiving physical therapy for gait, balance, or other lower extremity training;
* Known neuromuscular disorder or overt neurological disease (e.g. Multiple Sclerosis, Rhabdomyolysis, Myasthenia Gravis, Ataxia, Apraxia, post-polio syndrome, mitochondrial myopathy, Parkinson's Disease, ALS etc.)
* Unable to communicate because of severe hearing loss or speech disorder;
* Planned surgical procedure or hospitalization in the next 12 months (e.g., joint replacement, CABG);
* Severe pulmonary disease, requiring the use of supplemental oxygen;
* Terminal illness, as determined by a physician;
* Severe cardiac disease, including NYHA Class III or IV congestive heart failure, clinically significant aortic stenosis, recent history of cardiac arrest, use of a cardiac defibrillator, or uncontrolled angina;
* Is planning to move out of the area in next year or leave the area for \>6 mos during follow-up;
* Other significant conditions that would impact safety and/or compliance to the protocol (e.g. renal failure on hemodialysis, psychiatric disorder-bipolar, schizophrenia, excessive alcohol intake etc.);
-Actively enrolled in an intervention study
* Use of walker or wheel chair;
* Artificial hair covering the scalp such as a wig or toupee
* Failure to provide informed consent;
* Transaminases \>twice upper limit of normal;
* Hemoglobin \<10 g/dL;
* Investigator discretion based on safety or compliance concerns
* Abnormalities in blood chemistry parameters as defined above;
* Severe hypertension, e.g., SBP \> 200, DBP \> 110 mmHg;
* Uncontrolled diabetes or hyperglycemia (fasting blood glucose \> 126 mg/dl or hemoglobin A1C \> 6.5%)
* Other temporary events that would influence participation (e.g. episodic health event, sick spouse, bereavement, or recent move);
* Other conditions identified with medical history at enrollment that places the participant at risk for participation.
20 Years
110 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Institute on Aging (NIA)
NIH
University of Florida
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
David Clark, ScD
Role: PRINCIPAL_INVESTIGATOR
University of Florida
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Florida
Gainesville, Florida, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
OCR19439
Identifier Type: OTHER
Identifier Source: secondary_id
IRB201900001
Identifier Type: OTHER
Identifier Source: secondary_id
IRB202201585
Identifier Type: OTHER
Identifier Source: secondary_id
IRB201802227-N
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.